sector medic suppli devic
messag earlier today fda announc requir remain surgic
mesh product transvagin repair pelvic organ prolaps pop remov
market product subject safeti concern past
year lead signific legal liabil compani make
one remain player market view today move stock
vs flat outsiz rel compani exposur estim
revenu
pelvic mesh make wrong kind headlin transvagin mesh product
treatment pelvic organ prolaps subject class action suit
past year relat varieti complic women experienc subsequ
procedur boston quantifi total legal exposur believ mesh
repres bulk compani litig reserv last year
contribut cash qualifi settlement fund call manag
indic either settl final stage settl known
claim relat issu
fda commun kind boston thu far share
alreadi pressur past month vs
investor concern potenti impact fda recent physician
commun regard use peripher vascular product contain paclitaxel
advisori panel topic expect take place june context estim
world-wide sale boston eluvia de ranger drug-coat balloon
model call revenu ramp prior fda
announc result expect manag might choos
lower top end revenu guidanc rang upcom call
account uncertainti util product outcom fda
today announc repres anoth increment headwind boston
view reaction stock outsiz rel compani exposur
boston pelvic health segment contribut compani
urolog divis sale estim mesh roughli global howev
manag believ today announc specif appli two product
uphold xenform gener world-wide revenu last year
result remov product market would repres anoth
headwind compani would need overcom hit outlook believ
impact manag
creat bluematrix
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst research associ receiv compens base upon variou factor includ qualiti research investor client
feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc act financi advisor claret medic inc connect sale boston scientif corp
guggenheim secur llc affili expect receiv intend seek compens invest bank servic boston scientif
corpor next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori boston scientif corpor
creat bluematrix
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/or
cs coverag suspend guggenheim secur llc suspend coverag compani
nc cover guggenheim secur llc cover compani
monitor describ stock whose compani fundament financi monitor financi project opinion
invest merit compani provid
review ur follow releas signific news compani rate temporarili place review suffici
inform obtain assess analyst
guggenheim secur llc methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ restrict analys
market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash flow ev/ebitda price-to-earnings pe/growth
price-to-cf p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
price target assign buy- sell-rat stock price target neutral-r stock provid discret analyst
page analyst certif import disclosur
